The Relationship Between the Tumor Markers and Interstitial Lung Disease

October 22, 2020 updated by: Zhang Jianheng, The First Affiliated Hospital of Guangzhou Medical University

The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients.

This study was undertaken to investigate the source of these serum tumor markers.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 are often increased in interstitial lung disease patients.

This study was undertaken to investigate the source of these serum tumor markers.We hypothesis that these tumor markers are released from the lung.

The broncholveolr lvge fluid levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), CA125 were measured in the interstitial lung disease patients before lung transplantation. The immunohistochemical test was performed in the specimen lung after lung transplantation.

Study Type

Observational

Enrollment (Actual)

13

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • China
    • Guangdong
      • Guangzhou, Guangdong, China, 520120
        • The First Affiliated Hospital of Guangzhou Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

lung disease patients for lung transplantation

Description

Inclusion Criteria

1.Interstitial lung disease patients for lung transplantation

-

Exclusion Criteria:

  1. tumor
  2. Interstitial lung disease patients could not be performed by lung transplantation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
interstitial lung disease patients
interstitial lung disease patients who need lung transplantation
Other: No Intervention
No Intervention
non- interstitial lung disease patients
non- interstitial lung disease patients who need thoracic surgery to remove pneumatocele
Other: No Intervention
No Intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
serum levels of carcinoembryonic antigen (CEA)
Time Frame: 6months
serum levels of carcinoembryonic antigen (CEA)
6months
serum levels of carbohydrate antigen 19-9 (CA19-9)
Time Frame: 6months
serum levels of carbohydrate antigen 19-9 (CA19-9)
6months
serum levels of carbohydrate antigen 125(CA125)
Time Frame: 6months
serum levels of carbohydrate antigen 125(CA125)
6months
The alveolar lavage fluid levels of carcinoembryonic antigen (CEA)
Time Frame: 1 week
The alveolar lavage fluid levels of carcinoembryonic antigen (CEA)
1 week
The alveolar lavage fluid levels of carbohydrate antigen 19-9 (CA19-9)
Time Frame: 1 week
The alveolar lavage fluid levels of carbohydrate antigen 19-9 (CA19-9)
1 week
The alveolar lavage fluid levels of carbohydrate antigen 125
Time Frame: 1 week
The alveolar lavage fluid levels of carbohydrate antigen 125
1 week
The lung tissue levels of carcinoembryonic antigen (CEA)
Time Frame: 1 week
The lung tissue levels of carcinoembryonic antigen (CEA)
1 week
The lung tissue levels of carbohydrate antigen 19-9 (CA19-9)
Time Frame: 1 week
The lung tissue levels of carbohydrate antigen 19-9 (CA19-9)
1 week
The lung tissue levels of carbohydrate antigen 125
Time Frame: 1 week
The lung tissue levels of carbohydrate antigen 125
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2019

Primary Completion (Actual)

October 15, 2020

Study Completion (Actual)

October 15, 2020

Study Registration Dates

First Submitted

October 16, 2020

First Submitted That Met QC Criteria

October 16, 2020

First Posted (Actual)

October 22, 2020

Study Record Updates

Last Update Posted (Actual)

October 23, 2020

Last Update Submitted That Met QC Criteria

October 22, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • yilunshen2020145

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe